Filing Details

Accession Number:
0001638599-20-000976
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-17 16:05:47
Reporting Period:
2020-12-15
Accepted Time:
2020-12-17 16:05:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1535955 Lipocine Inc. LPCN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1266062 R Morgan Brown 675 Arapeen Drive
Suite 202
Salt Lake City UT 84010
Evp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-12-16 28,125 $0.00 202,941 No 4 M Direct
Common Stock Disposition 2020-12-16 8,437 $1.35 194,504 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Acquisiton 2020-12-15 160,000 $1.37 160,000 $1.37
Common Stock Restricted Stock Unit Acquisiton 2020-12-16 28,125 $0.00 28,125 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
160,000 2021-12-15 2030-12-15 No 4 A Direct
28,125 2020-12-16 2027-01-25 No 4 M Direct
Footnotes
  1. Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 15, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.
  2. Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO.
  3. Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units.
  4. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.